• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

SeraCare Acquisitions, Inc. 09-Jan-02

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug & Administration

Kansas City District

Southwest Region

P.O. Box 15905

Lenexa, Kansas 66285-5905

Telephone: (913) 752-2100

January 9, 2002

CERTIFIED MAIL

RETURN RECEIPT REQUESTED

WARNING LETTER

Ref. KAN 2002-01

Claus L. Winther, President

SeraCare Acquisitions, Inc.

919 West Cucharras

Colorado Springs, CO 80905

Dear Mr. Winther:

Recently an inspection was made of your plasma donor facility located at 1301 SW Topeka Avenue, Suite 3, Topeka, Kansas. This inspection was conducted on November 27 through December 12, 2001, by a Food and Drug Administration Investigator from this office who documented deviations from Title 21, Code of Federal Regulations, Parts 600-680. These deviations cause the plasma products prepared at this location to be adulterated within the meaning of Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (Act). The deviations found include, but are not limited to, the following:

Failure to assure that personnel responsible for product distribution had the necessary training and experience required to determine that the final product was acceptable [21 CFR 606.20(b)]. For example:

The center manager and assistant manager were involved with the improper release of

units of plasma that were HCV reactive, and units of plasma collected from a donor

known to have been incarcerated for greater than 72 hours. Both employees were

involved with product distribution responsibilities before they had received supervisory

certification, and with little experience in distribution operations. The assistant

manager performed these duties prior to receiving related training.

Failure of employees to consistently follow Standard Operating Procedures (SOPS) pertaining to donor

suitability and plasma collection [21 CFR 606.100(b)]. Examples include:

SOP 60.7 (Handling Reactive Viral Marker Results)

Donors with permanent or temporary deferrals are being allowed to donate.

Not always submitting the Look Back/Alert Notification within the two-day time limit

after receipt of reaction information.

SOP 50.1 (Hypotensive/Vaso Vagal Reactions)

The Medical Incident Report form (MIR) is not always completed according to the SOP. For instance no documentation of QA reviews on some forms, and a MIR not being prepared for almost three weeks after an incident of vaso vagal reaction.

SOP 20.8 (Hematocrit Determination)

This SOP is not always followed with regard to the documentation of out-of-range

readings.

Failure to consistently review and document investigations and corrective actions regarding errors found in records, prior to the release or distribution of plasma products. [21 CFR 606.100(c)].

Failure to submit reportable blood product deviations to the Food and Drug Administration within 45 days of discovery [21 CFR 600.14(a)].

This letter is not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure adherence to each requirement of the Act and regulations. You should know that these serious violations of the law may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, seizure and/or obtaining a court injunction against further manufacturing of your blood products.

We have received a letter dated January 4 from Mr. Charles Auger, Director of Quality, which is his response to the FDA 483 observations. Mr. Auger?s letter was taken into account for the preparation of this Warning Letter. We will respond to Mr. Auger by a separate letter.

It is necessary for you to take action on this matter now. Please let this office know in writing within fifteen (15) working days from the date you received this letter, if Mr. Auger?s letter should be considered as a response to this letter, or of other steps you are taking to correct the problems. We also ask that you explain how you plan to prevent this from happening again. If you need more time, let us know why and when you expect to complete your correction.

Your reply should be sent to Clarence R. Pendleton, Compliance Officer, at the above address.

Sincerely,

Charles W. Sedgwick

District Director

Kansas City District